Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.
The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from ...
The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech ...
Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class ...
Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted ...
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally ...
The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what ...
The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results